Transfer factor in the treatment of chronic mucocutaneous candidiasis: a controlled study.
A controlled cross-over study with transfer factor was carried out on 7 patients suffering from chronic mucocutaneous candidiasis. Only one patient showed clinical improvement, which started during a period of pretreatment with 5-fluorocytosine given orally 14 days before the patient entered this trial. No conversion to a positive skin test with Candida antigen or PPD was demonstrated following TF in the 6 patients who were anergic to either of these antigens. Variations in the cell-mediated immune response as revealed by lymphocyte transformation were observed in most patients, especially when studied over a long period of time. However, no pronounced efficacy of TF vis-à-vis placebo in normalizing the cell-mediated immune response could be demonstrated in the 5 patients who completed the clinical trial. Systemic side effects were not observed.
D000293:Adolescent; D000328:Adult; D002179:Candidiasis, Cutaneous / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009092:Mucous Membrane / Q000473:pathology; D010919:Placebos; D012882:Skin Tests; D014165:Transfer Factor / Q000627:therapeutic use*
D010919:Placebos; D014165:Transfer Factor; D005437:Flucytosine